Clinical trial NCT00112866 (phase 2, status: terminated)
Conditions: adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor
ICD codes: G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: cilengitide
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed intracranial glioblastoma multiforme (GBM)

               -  Original diagnosis of low-grade glioma with subsequent histological confirmation
                  of GBM allowed

               -  Recurrent disease

                    -  Failed prior radiotherapy

          -  Must require a surgical procedure (gross total or near gross total resection) for
             tumor removal

          -  Performance status - Karnofsky 60-100%

          -  White Blood Count (WBC) ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)

          -  Serum glutamic oxaloacetic transaminase (SGOT) < 2 times upper limit of normal (ULN)

          -  Bilirubin < 2 times ULN

          -  Creatinine < 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for ≥ 2 weeks
             after study participation (for female patients) or for 3 months after study
             participation (for male patients)

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No active infection

          -  No other significant uncontrolled medical illness that would preclude study
             participation

          -  At least 3 weeks since prior interferon

          -  No prior cilengitide

          -  No other prior targeted antiangiogenic treatment (e.g., vatalanib, SU5416, or
             thalidomide)

          -  No concurrent anticancer immunotherapy

          -  No concurrent routine prophylactic filgrastim (G-CSF)

          -  At least 2 weeks since prior vincristine

          -  At least 3 weeks since prior procarbazine

          -  At least 6 weeks since prior nitrosoureas

          -  No concurrent anticancer chemotherapy

          -  At least 3 weeks since prior tamoxifen

          -  No concurrent anticancer hormonal therapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent anticancer radiotherapy

          -  Recovered from all prior therapies

          -  No more than 3 prior treatments for GBM (1 initial treatment; and treatment for 2
             relapses)

               -  For patients who received prior therapy for low-grade glioma, a subsequent
                  surgical diagnosis of high-grade glioma is considered the first relapse

          -  At least 4 weeks since prior investigational agents

          -  At least 4 weeks since prior cytotoxic therapy

          -  At least 3 weeks since other prior non-cytotoxic therapy (e.g., isotretinoin), except
             radiosensitizers

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational agents